Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has a beta value of 1.8 and has seen 2,013,027 shares traded in the recent trading session. The company, currently valued at $31.64 Million, closed the recent trade at $0.284 per share which meant it lost $0 on the day or -0.35% during that session. The SNSS stock price is -297.89% off its 52-week high price of $1.13 and 29.58% above the 52-week low of $0.2. If we look at the company’s 10-day average daily trading volume, we find that it stood at 16.8 Million shares traded. The 3-month trading volume is 3.32 Million shares.

The consensus among analysts is that Sunesis Pharmaceuticals, Inc. (SNSS) is a Hold stock at the moment, with a recommendation rating of 2.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 4 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.06.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) trade information

Despite being -1.75% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the SNSS stock price touched $0.389 or saw a rise of 28.07%. Year-to-date, Sunesis Pharmaceuticals, Inc. shares have moved -17.15%, while the 5-day performance has seen it change -54.98%. Over the past 30 days, the shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have changed -28.26%. Short interest in the company has seen 1.4 Million shares shorted with days to cover at 0.42.

Wall Street analysts have a consensus price target for the stock at $0.75, which means that the shares’ value could jump 164.08% from current levels. The projected low price target is $0.5 while the price target rests at a high of $1. In that case, then, we find that the current price level is +252.11% off the targeted high while a plunge would see the stock lose 76.06% from current levels.

Sunesis Pharmaceuticals, Inc. (SNSS) estimates and forecasts

Figures show that Sunesis Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -17.73% over the past 6 months, with this year growth rate of -18.52%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 33.3% and 16.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be -74%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +42.6% over the past 5 years. Earnings growth for 2020 is a modest +64.2% while over the next 5 years, the company’s earnings are expected to increase by 0%.